A retrospective clinical analysis of very elderly patients with lymphoma in a single institute
演題番号 : PS-1-157
山本 英督 （Hidesuke Yamamoto):1、花村 一朗 （Ichiro Hanamura):1、内野 かおり （Kaori Uchino):1、水谷 元紀 （Motonori Mizutani):1、堀尾 知弘 （Tomohiro Horio):1、高橋 美裕希 （Miyuki Takahashi):1、水野 昌平 （Shohei Mizuno):1、後藤 峰明 （Mineaki Goto):1、後藤 麻友子 （Mayuko Goto):1、恒川 敬和 （Norikazu Tsunekawa):1、若林 基弘 （Motohiro Wakabayashi):1、渡会 雅也 （Masaya Watarai):1、三輪 啓志 （Hiroshi Miwa):1、仁田 正和 （Masakazu Nitta):1
1:Dept. Int. Med., Div. Hematol., Aichi Medical University, Nagakute, Japan
The prevalence of malignant lymphoma (ML) is expected to rise because of aging population in Japan. Many patients with ML are aged, and very elderly patients are usually vulnerable, which will influence treatment strategies and outcomes. In this study we analyzed clinical data of very elderly patients with ML in our hospital to optimize treatment efficacy among these patients. We retrospectively analyzed 15 very elderly patients with ML aged over 85 years. They were newly diagnosed between Jan 2000 and Feb 2013 in our hospital. The median age was 89 years (85-96), and 6 patients were male and 9 were female. The distribution of clinical stage I/II/III/IV was 5/2/2/6. There were 9 in diffuse large B-cell lymphoma, 3 in B-cell lymphoma unclassified, 1 in MALT lymphoma, 1 in extranodal NK/T lymphoma, and 1 in Primary cutaneous follicle centre lymphoma. The number of patients treated with R-COP, R-THP-COP, rituximab, COP, CHOP and non-therapy was 4, 4, 2, 2, 1 and 2. Administration dose of anti-cancer drugs was reduced in all patients. At the time of analysis (a median follow-up: 492 day), 3-year OS were 63%, CR rate was 40% in all patients. The most affecting factor for OS was sex (F vs M, not reached vs 4.9m, p=0.01). The better performance status showed better OS (PS 0-1 vs 2-4, not reached vs 6.4m, p=0.22). Female patients showed better OS. PS might be associated with longer survival. We need analyze more patients to clarify the features of these ML.